Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science

References

• Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 353(23), 2477–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581–592 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335(12), 865–875 (1996).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma; a double-blind, randomized, placebo-controlled, Phase III trial. Lancet 372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378(9807), 1931–1939 (2011).
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: a critical review. Eur. J. Clin. Med. Oncol. 2, 67–72 (2011).
   Google Scholar
• Heng DY, Mackenzie MJ, Vaishampayan UN et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549–1555 (2012).
   PubMed Web of Science ®Google Scholar
• Swanton C, Larkin JM, Gerlinger M et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med. 2(8), 53 (2010).
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The von Hippel–Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13(2 Pt 2), 680s–684s (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 373(9669), 1119–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 a and 2 a on mTORC1 and mTORC2. J. Biol. Chem. 283(50), 34495–34499 (2008).
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12(1), 9–22 (2007).
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer. 6, 729–734 (2006).
   Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complex. Science 307(5712), 1098–1101 (2005).
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22, 159–168 (2006).
   PubMed Web of Science ®Google Scholar
• Zeng Z, Sarbassov dos D, Samudio IJ et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109(8), 3509–3512 (2007).
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res. 15(16), 5020–5025 (2009).
   PubMed Web of Science ®Google Scholar
• Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48–62 (2011).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Jänne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8(9), 709–723 (2009).
   PubMed Web of Science ®Google Scholar
• Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin. Cancer Res. 16(7), 1973–1978 (2010).
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang L, Chang W, Sun B, Groh M, Speicher A, Lou H. Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans. PLoS ONE 6(12), e28953 (2011).
   PubMed Web of Science ®Google Scholar
• Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15(3), 167–170 (2009).
   PubMed Web of Science ®Google Scholar
• Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70(3), 1063–1071 (2010).
   PubMed Web of Science ®Google Scholar
• Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev. Mol. Diagn. 9(3), 231–241 (2009).
   PubMed Web of Science ®Google Scholar
• Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549–1555 (2011).
   PubMedGoogle Scholar
• Albiges L, Lacovelli R, Porta C et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib in metastatic renal cell carcinoma: is there any active treatment? Eur. J. Cancer 47(Suppl. 1), (2011) (Abstract 7143).
   Google Scholar
• Busch J, Seidel C, Weikert S et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer 11, 295 (2011).
   PubMedGoogle Scholar
• Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol. Ther. 10(7), 658–664 (2010).
   PubMed Web of Science ®Google Scholar
• Brannon AR, Rathmell WK. Renal cell carcinoma: where will the state-of-the-art lead us? Curr. Oncol. Rep. 12(3), 193–201 (2010).
   PubMedGoogle Scholar